Attached files
file | filename |
---|---|
EX-23.1 - CONSENTOF BUCHBINDER TUNICK & COMPANY LLP, INDEPENDENT REGISTERED PUBLIC ACCOUNT - ELITE PHARMACEUTICALS INC /NV/ | f10k2020ex23-1_elite.htm |
EX-32.1 - CERTIFICATION - ELITE PHARMACEUTICALS INC /NV/ | f10k2020ex32-1_elite.htm |
EX-31.2 - CERTIFICATION - ELITE PHARMACEUTICALS INC /NV/ | f10k2020ex31-2_elite.htm |
EX-31.1 - CERTIFICATION - ELITE PHARMACEUTICALS INC /NV/ | f10k2020ex31-1_elite.htm |
EX-10.54 - JULY 29, 2019 AMENDMENT TO THE LICENSE, SUPPLY AND DISTRIBUTION AGREEMENT BETWEE - ELITE PHARMACEUTICALS INC /NV/ | f10k2020ex10-54_elite.htm |
EX-10.53 - JUNE 21, 2019 RETENTION AGREEMENT WITH DOUGLAS PLASSCHE - ELITE PHARMACEUTICALS INC /NV/ | f10k2020ex10-53_elite.htm |
EX-10.52 - EMPLOYMENT AGREEMENT WITH DOUGLAS PLASSCHE - ELITE PHARMACEUTICALS INC /NV/ | f10k2020ex10-52_elite.htm |
EX-4.6 - DESCRIPTION OF COMMON STOCK - ELITE PHARMACEUTICALS INC /NV/ | f10k2020ex4-6_elite.htm |
10-K - ANNUAL REPORT - ELITE PHARMACEUTICALS INC /NV/ | f10k2020_elitepharma.htm |
Exhibit 32.2
CERTIFICATION
PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE
SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report of Elite Pharmaceuticals, Inc. (the “Company”) on Form 10-K for the year ended March 31, 2020 filed with Securities and Exchange Commission (the “Report”), I, Carter J. Ward, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
1. | The Report fully complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934; and |
2. | The information contained in the Report fairly presents, in all material respects, the consolidated financial condition of the Company as of the dates presented and the consolidated result of operations of the Company for the periods presented. |
Date: June 29, 2020 | /s/ Carter J. Ward |
Carter J. Ward Chief Financial Officer, Treasurer and Secretary (Principal Accounting and Financial Officer) |
This certification has been furnished solely pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
A signed original of this written statement required by Section 906 has been provided to Elite Pharmaceuticals, Inc. and will be retained by Elite Pharmaceuticals Inc. and furnished to the Securities and Exchange Commission or its staff upon request.